Grants & Projects per year
Personal profile
Fingerprint
Dive into the research topics where Carla Frederick is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
STRC: 2024 Success with Therapies Research Consortium (STRC) Award Frederick
Frederick, C. (PI)
08/1/24 → 07/31/26
Project: Research
-
VX20-121-103: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G
Frederick, C. (PI)
Vertex Pharmaceuticals Incorporated
11/16/21 → 12/31/26
Project: Research
-
VX20-121-102:A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects with Cystic Fibrosis Who are Heterozygous for F508del and a Minimal Function Mutation
Frederick, C. (PI)
Vertex Pharmaceuticals Incorporated
11/11/21 → 12/31/26
Project: Research
-
MAYFLOWERS: A Prospective Study Evaluating Maternal and Fetal Outcomes in the ERA of Modulators
Frederick, C. (PI)
04/1/21 → 12/1/26
Project: Research
-
Longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis: PROMISE-ENDO
M.YcazaMariafor the PROMISE Endocrine Sub-study Group, May 2026, In: Journal of Cystic Fibrosis. 25, 3, p. 457-465 9 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years after Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO
PROMISE Endocrine Substudy Group, Sep 1 2025, In: Journal of Clinical Endocrinology and Metabolism. 110, 9, p. 2674-2684 11 p.Research output: Contribution to journal › Article › peer-review
24 Scopus citations -
Physical well-being and burden of care in adults on modulator therapy: A mixed methods study of patient-reported experiences from the Well-ME survey
Brown, C. D., Frederick, C., Yu, E., Zagnit, E., King, J. R. & Van Citters, A. D., Jul 2025, In: Journal of Cystic Fibrosis. 24, 4, p. 652-659 8 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
VX20-121-102 Study Group & VX20-121-103 Study Group, Mar 2025, In: The Lancet Respiratory Medicine. 13, 3, p. 256-271 16 p.Research output: Contribution to journal › Article › peer-review
Open Access86 Scopus citations -
Wellness in the modulator era: An observational study of the impact of CFTR modulator therapy on the well-being of people with cystic fibrosis
Van Citters, A. D., Aliaj, E., Alvarez, J. A., Brown, C. D., Cary, J., Cravens, R., Frederick, C. A., Georgiopoulos, A. M., Goss, C. H., Kazmerski, T. M., King, J. R., Lawrence, M., Lovell, C., Roman, C., Tillman, L. & Yu, E., Jul 2025, In: Journal of Cystic Fibrosis. 24, 4, p. 642-651 10 p.Research output: Contribution to journal › Article › peer-review
Open Access20 Scopus citations